UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
|Articles|April 8, 2014
VIDEO: Pfizer's Dave Moules on the relationship between payers and pharmaceutical manufacturers
Exclusive video of Pfizer's Dave Mouleson the relationship between payers and pharmaceutical manufacturers.
Advertisement
Dave Moules, with Pfizer in New York, talks about the key in the relationship between payers and pharmaceutical manufacturers in this exclusive video interview with Managed Healthcare Executive.
Advertisement
Related to this article
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
Jessica Castle, M.D., discusses CGM’s A1C impact in non-insulin type 2 diabetes
5